Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, has announced the promotion of Thomas Englese to the position of chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will now lead the company's commercial strategy and operations. His responsibilities include overseeing sales, marketing, market access, and commercial operations for TONMYA, the company's treatment for fibromyalgia in adults, as well as its acute migraine products Zembrace SymTouch and Tosymra.
The promotion comes at a critical time for Tonix as it works to expand the reach of TONMYA, which was recently approved and represents the first new treatment for fibromyalgia in over 15 years. The announcement highlights the company's commitment to strengthening its commercial infrastructure and maximizing the product's potential in the market. Seth Lederman, president and CEO of Tonix, emphasized Englese's instrumental role in building the company's commercial organization and launching TONMYA, noting that his leadership has been key to the company's progress.
Englese expressed his enthusiasm for the new role and the company's direction, stating that Tonix is focused on expanding access to TONMYA, growing its patient and prescriber base, and increasing sales as it broadens the product's launch. This strategic focus is essential for the company to establish a strong foothold in the fibromyalgia treatment market, which has seen limited innovation for years.
The importance of this announcement extends beyond the company itself. Tonix's progress with TONMYA could have significant implications for patients suffering from fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties. With a new treatment option available, patients may have access to a therapy that could improve their quality of life. Additionally, the company's continued investment in its commercial team reflects the competitive nature of the biopharmaceutical industry, where effective commercialization is critical to the success of new drugs.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on developing treatments for central nervous system (CNS) and immunology conditions with high unmet medical needs. Beyond TONMYA, the company's CNS portfolio includes products for acute migraine, as well as investigational candidates such as TNX-2900 for Prader-Willi syndrome, a rare disease. The company is also advancing its immunology pipeline, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
As Tonix continues to expand its commercial operations, the promotion of Englese signals a strategic emphasis on driving the adoption of TONMYA and maximizing its commercial success. The company's efforts to broaden the launch and increase patient access could have a lasting impact on the fibromyalgia treatment landscape. For more information on the company and its latest developments, visit the Tonix newsroom.
